Literature DB >> 9209907

Chemotherapy for advanced non-small cell lung cancer.

R S Herbst1, N H Dang, A T Skarin.   

Abstract

Lung cancer is the most lethal cancer in both men and women. Given that chemotherapy for advanced disease is marginally beneficial and noncurative, its use must be governed judiciously, with each decision being evaluated individually for each patient. Chemotherapy for lung cancer has progressed over the past decade, and with the advent of new agents, its future looks promising.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209907     DOI: 10.1016/s0889-8588(05)70445-7

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  2 in total

1.  Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin.

Authors:  Zhao-Jia Gao; Wei-Dong Yuan; Jun-Qiang Yuan; Kai Yuan; Yong Wang
Journal:  Med Sci Monit       Date:  2018-02-22

2.  Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.

Authors:  Hendrik Fischer; Ninon Taylor; Sigrid Allerstorfer; Michael Grusch; Gudrun Sonvilla; Klaus Holzmann; Ulrike Setinek; Leonilla Elbling; Heidelinde Cantonati; Bettina Grasl-Kraupp; Christine Gauglhofer; Brigitte Marian; Michael Micksche; Walter Berger
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.